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p= 0.03), use of 3rd generation SU (OR= 0.86 [0.78 - 0.95]; p= 0.002), and chronic renal 
disease (OR= 1.34 [1.07 - 1.67]; p= 0.01). ConClusions: In conclusion, multiple fac-
tors, including efficacy and hypoglycemia, are associated with discontinuation of 
SU treatment after insulin initiation.
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objeCtives: Sulfonylurea (SU) may be discontinued or down-titrated due to 
hypoglycemia. Hypoglycemia may be more concerning for patients not receiving 
aggressive efficacy-driven treatment such as the dual-therapy of SU and insulin. A 
retrospective cohort study using the MarketScan database was conducted to assess 
the association between hypoglycemia and therapy changes (discontinuation or 
down-titration) among adults receiving SU therapy without insulin. Methods: 
Patients with the first SU prescription (Rx) (index date) in 2009-2011, ≥ 18 years 
of age on the index date, and with ≥ 1 year continuous enrollment pre- and post-
index were included. Patients were excluded if they received insulin within the 
1-year pre- or post-index, had ≥ 2 SUs on the index date, or had type 1, gestational 
or secondary diabetes. Therapy changes were determined during the 1-year post-
index period. Discontinuation occurred when consecutive SU fills were ≥ 90 days 
apart. Down-titration occurred when an SU fill had a lower equivalent dose than 
the index dose. Hypoglycemic events were identified using ICD-9 code between the 
index date and the therapy change or the end of the 1-year post-index period. Cox 
regression was used to evaluate the association between hypoglycemic events and 
therapy changes. Results: 97,570 patients were included in the study, of which 
50,854 (52.1%) experienced therapy changes within 1-year post-index. Patients with 
hypoglycemic events were at significantly higher risk for therapy changes (HR= 
1.86 [1.75, 1.97]; p< . 01). Specifically, they were 197% more likely to down-titrate 
(HR= 2.97 [2.53, 3.46]; p< . 01) and 80% more likely to discontinue (HR= 1.80 [1.69, 1.92]; 
p< . 01). ConClusions: Post-index hypoglycemic events are significantly associ-
ated with therapy changes among patients receiving SU without insulin, especially 
down-titration.
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objeCtives: To evaluate doctors’ adherence to Malaysian Clinical Practice 
Guideline (CPG) 2009 in the management of diabetes mellitus with co-morbidities 
in Malaysia. Methods: Cross-sectional study was done at a tertiary-care hospital 
in Malaysia. Total 51 physicians and 1020 patients’ prescriptions written by same 
physicians (20 prescriptions per physician) were analyzed. All patients had diabetes 
mellitus with co-morbidities. Depending on the recommendations of CPG 2009, 
the prescriptions were clustered as adherent and non-adherent prescriptions. All 
obtained data were analyzed using descriptive and inferential statistics. Results: A 
statistically significant negative association (Ф= 0.094, p-value= 0.003) was observed 
between diabetes mellitus control and co-morbidities. CPG adherent had statisti-
cally weak negative association (Ф= - 0.081, p-value= 0.010) with patients having 
co-morbidities (41.6%). No statistically significant association was observed between 
CPG adherence and any other co-morbidity. Majority of the patients received guide-
lines-compliant pharmacotherapy. The overall good level of physician adherence 
with CPG 2009 was observed in the management of diabetes mellitus with co-
morbidities. ConClusions: The study explored several features of prescription 
pattern of the physicians involved in the management of diabetes mellitus with 
co-morbidities and recognized the need for improvement in their prescription pat-
tern for treating the diabetes mellitus.
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objeCtives: Diabetes is associated with a number of microvascular and macrovas-
cular complications. Diabetic macular edema (DME) is one of these complications 
and is among the leading causes of vision impairment. However, little data exists 
as to the patient-related burden of DME in Europe and the aim of the current study 
was to address this gap. Methods: Data from the 2013 5EU (France, Germany, Italy, 
Spain, and UK) National Health and Wellness Survey (NHWS) were used (N= 62,000). 
The NHWS is a patient-reported survey administered to a demographically rep-
resentative sample of adults (with respect to age, sex, and region). Patients who 
reported experiencing DME were compared with a propensity-scored matched con-
trol group of patients with diabetes but without DME. Matching variables included 
demographics, comorbidities (Charlson comorbidity index [CCI]), and diabetes 
history. Post-match, patients with DME and matched controls were compared on 
health outcomes (SF-36v2, Work Productivity and Activity Impairment, and self-
reported health care resource utilization) using general linear models. Results: 
4,088 patients reported diabetes (6.6%). Of these, 296 (7.2%) reported having DME. 
Patients with DME were more likely to have type 1 diabetes (26.4% vs. 8.5%), had been 
diagnosed with diabetes for longer (54.4% vs. 20.7% were diagnosed 16+ years), were 
more likely to use insulin (68.6% vs. 27.3%), and had a greater comorbidity burden 
(CCI = 2.2 vs. 1.6) (all p< .05), among other differences. After matching on these 
variables, patients with DME (n= 286) reported significantly worse physical health 
status (PCS: 41.1 vs. 43.2), greater overall work impairment (36.2% vs. 25.64%), and 
objeCtives: HIPOS-ER is the first national Hypoglycemia study in Portugal col-
lecting specific resource data directly in the hospitals. Here we aim to describe 
the average cost of severe hypoglycemic event by anti-hyperglycemic agent (AHA) 
class. Methods: The study was conducted in 7 centers in mainland Portugal for 
a period of 12 months (Jan13-Jan14). Patient level data and resource utilization 
were collected. Unit costs for 2014 were extracted from official sources. Regarding 
emergency room (ER) attendance, costs were calculated multiplying resource use by 
corresponding unit costs. For hospitalization, length of stay was multiplied by daily 
cost obtained through hospital account record. AHA therapy classes were: Group 1 
(insulin), Group 2 (secretagogue), Group 3 (oral AHA excluding secretagogue), and 
Group 4 (at least one insulin and one secretagogue). Results: 238 patients were 
enrolled and 105 (44%) were hospitalized. The distribution based on AHA therapy: 
55% (131) Group 1, 32% (75) Group 2, 7% (16) Group 3 and 7% (16) Group 4. After ER 
episode, Group 2 patients were more often hospitalized versus Group 1 (71% vs. 29%; 
p< 0.001) and Group 4 (31%; p= 0.003). The global cost was 1,493€ (34€ -26,818€ ) and 
hospitalization was the main cost driver accounting for 85% of costs. The total cost 
per AHA class was: Group 1: 1,309€ ; Group 2: 1,880€ ; Group 3: 1,350€ ; Group 4: 1,330€ . 
When comparing ER-only vs. hospitalized: Group 1: 167€ vs. 4,105€ ; Group 2: 185€ 
vs. 2,583€ ; Group 3: 156€ vs. 2,278€ ; Group 4: 237€ vs. 3,734€ . Group 1 accounted for 
48% of overall costs, Group 2 40%, Groups 3 and 4, 6% each. Group 2 had the highest 
hospitalization rate (70.7%). ConClusions: AHA classes may contribute differently 
for costs associated with severe hypoglycemia. Insulin based therapy had the great-
est overall cost followed closely by secretagogue type drugs, which were associated 
with more hospitalizations.
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objeCtives: The aim of this study was to assess the burden of severe hypogly-
cemia (HYPO) and diabetes ketoacidosis (DKA) in terms of incidence, treatment 
patterns and cost in Italy. Methods: Eligible patients were identified through a 
data warehouse (DENALI), which matches with a probabilistic linkage demographic, 
clinical and economic data of about 9.9 million individuals of Lombardy region. The 
study population was made of all individuals with a diagnosis of type-1 diabetes 
(T1DM) who, during the period 1-1-2000 to 31-12-2010 developed a first episode of 
severe HYPO (ICD-9-CM: 251.0-251.2) or DKA (ICD-9-CM: 250.10-250.13) leading to 
hospitalization (index event). The identified individuals were followed-up from the 
index event to a maximum of 10 years. We evaluated demographic characteristics 
of the study population and costs (hospitalizations, drugs and outpatient exami-
nations/visits) from the National Health Service’s perspective. Results: During 
the observational period 1,321 T1DM subjects had at least one hospital admission 
for HYPO (27.5%) or DKA (72.5%) event. Median age (min-max) at the first HYPO 
or DKA event was 66.9 (1.3-96.7) and 39.4 (1.0-95.7) years, respectively. The overall 
mortality was 14.3 deaths/100 patient-years among HYPO subjects and 7.0 among 
DKA ones: the difference in mortality rates between groups disappeared once 
controlling for age. The mean costs with 95% C.I. (€ /patient-year) for HYPO and 
DKA patients were, respectively 10,442 (8,755-12,129) and 9,720 (8,659-10,782) in 
the event year, 10,296 (8,446-12,145) and 5,805 (4,539-7,071) in the year before the 
event, and 5,619 (3,841-7,398) and 4,974 (3,912-6,035) in the year after the event. 
Hospitalizations represented the driver of total costs: in the year of event and in the 
year after it varied from 70 to 56% and 76 to 60% for HYPO and DKA patients, respec-
tively. ConClusions: This study attempted to address the burden of severe T1DM 
HYPO and DKA events in Italy in an unselected population. The burden showed to 
be relevant in terms of incidence, mortality and costs.
DIaBetes/enDocrIne DIsorDers – Patient-reported outcomes & Patient 
Preference studies
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objeCtives: Sulfonylureas (SU) represent a common treatment for type 2 diabetes 
(T2DM), but they are associated with hypoglycemia, weight gain, and possibly car-
diovascular events. The purpose of this study is to evaluate factors associated with 
SU discontinuation after insulin initiation. Methods: Patients ≥ 21 years old with 
a T2DM diagnosis between 2005 and 2012 were identified using the GE electronic 
medical records database. Index date was defined as the first insulin prescription 
(Rx) between 2006 and 2011. Patients were required to be on SU at the index date. 
Patients were excluded if they did not have medical records available ≥ 12 months 
before and after index date, were receiving insulin in the 12 months prior to index 
date, or had other forms of diabetes. Treatment with other diabetes medications in 
addition to SU and insulin were permitted in this study. SU discontinuation occurred 
when the gap between the end date of current SU Rx supply and the start date of 
subsequent SU supply was ≥ 90 days apart. Multivariate logistic regression was 
performed to identify factors associated with SU discontinuation. Results: A total 
of 8,185 patients were selected, with mean age 64 years and 49% were male. 60.4% 
discontinued their SU Rxs within 1 year, with a median time from insulin initia-
tion to SU discontinuation of 88 days. In the logistic regression, baseline diagnosed 
hypoglycemia (OR= 2.29 [95% CI 1.03 - 5.10]; p= 0.04) and baseline HbA1c (OR= 1.04 
[1.01 - 1.06]; p= 0.004) were identified as factors associated with SU discontinuation. 
Additional factors included BMI (< 25 kg/m2 vs. ≥ 30 kg/m2; OR= 1.23 [1.03 - 1.46]; 
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re-use of eDiaries previously used by patients doing fingerstick tests poses a low and 
acceptable risk; flexibility for handling measurements should be incorporated in the 
eDiary design including batch and individual reporting, reporting hypoglycaemic 
events as part of a meal event or as a standalone event and edit checks should be 
included to identify where a number of low measurements relate to the same event; 
there should be clear guidance to patientson how to transfer measurements to the 
eDiary; a method for managing control test measurementsshould be incorporated; 
and integrating glucometer measurements decreases patient burden and increases 
patient engagement.
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objeCtives: The 347 million people who live with diabetes face an array of daily 
disease management tasks, e. g. measuring blood glucose, keeping track of the nutri-
tional value of meals, and monitoring insulin usage. Diabetes trials vary in method-
ology, level of patient burden, volume of data captured and patient compliance. Our 
aim was to develop an electronic data capture system for use in clinical trials which 
would decrease patient burden while increasing compliance and improving data 
quality. Methods: We developed a diabetes specific, electronic, event driven diary 
for capturing data relevant for clinical trials. Iterations of the diary were tested in 
diabetes patients via focus groups and one-on-one usability evaluations. Feedback 
was analysed to understand the typical day-to-day experience of living with diabe-
tes, and to examine the impact and acceptability of a tailored electronic solution. 
Feedback was incorporated into a refined solution for use in clinical trials. Results: 
The nature of diabetes means that patients are typically very actively engaged in 
managing their disease, although a lot of variation was seen in patients and their 
management routines. The requirement for multiple devices and high volume of 
data was also reported as burdensome. The focus groups and usability studies high-
lighted the benefit of providing a flexible solution, as well as redesigning the diary 
from unstructured blood glucose measurement reporting to event driven reporting. 
This redesign met the needs of patients, as well as the requirements of clinical trial 
protocols. Patients agreed that they would prefer this integrated, intuitive solution 
over traditional paper and electronic solutions. ConClusions: When faced with 
the task of recording patient data in diabetes, a well-designed and thoroughly tested 
electronic solution can reduce burden and increase patient satisfaction. This in turn 
improves compliance, data quality and overall study efficiency, while meeting the 
needs of all stakeholders.
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objeCtives: Treatments for Type 2 Diabetes Mellitus (T2DM) are associated with 
varying effectiveness and safety profiles. Patients’ preferences for each of the medi-
cation characteristics that yield these varying profiles can be assessed through 
discrete choice experiments (DCEs). This study expands on the knowledge from 
two previous T2DM DCE studies conducted in the United Kingdom (UK) and the 
United States (US), and was aimed at evaluating the relative importance of medi-
cation attributes that influence medication choice among participants with T2DM 
from Germany. Methods: A web-based DCE was conducted among patients with 
self-reported T2DM from Germany. The DCE was designed to examine 7 attributes 
of T2DM medications (efficacy, urinary tract infection/genital infection side effects, 
nausea/other gastrointestinal side effects, weight change, and hypoglycemic events, 
treatment in case of low blood sugar, and blood pressure). Part-worth utilities were 
estimated using multi-logit models, and relative importance [RI] values were cal-
culated for each attribute. Results: N= 600 Participants with T2DM completed the 
study (50% male; mean age= 58.2 years SD= 10.0; BMI= 32.4, SD= 6.8). The RI values 
for the attributes in order of importance were: treatment in case of low blood sugar 
(22.5%), hypoglycemic events (18.1%), weight change (17.5%), efficacy (15.0%), nau-
sea/other gastrointestinal side effects (12.9%), UTI/genital infection side effects 
(7.9%), and blood pressure (6.0%). ConClusions: The results of this study suggest 
that hypoglycemic events and the interventions required in the case of such events 
are of great importance to patients; these two attributes represent over 40% of the 
variance in patients’ medication decisions. Change in body weight as a consequence 
of treatment was also an important attribute to patients. The results may help treat-
ment providers and payers to understand the preferences of patients with T2DM. 
Understanding these preferences may be useful in devising strategies for success-
fully engaging and maintaining patients on T2DM treatments.
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objeCtives: Hypoglycaemia is the main side-effect of insulin therapy and can 
prevent optimal diabetes management. Real-world data on the frequency and 
impact of non-severe (self-treated) hypoglycaemic events are scarce. Self-reported 
frequency of non-severe hypoglycaemic events (NSHEs), their impact on personal 
well-being, work productivity and health care resource use, and patient–physician 
communication following non-severe events, were examined in people taking insu-
lin. Methods: Adults in the UK aged > 15 years with Type 1 or insulin-treated Type 2 
diabetes mellitus (T1DM or T2DM) completed ≤ 4 questionnaires at weekly intervals 
(7-day recall). Severe hypoglycaemic events (requiring external assistance) are not 
more health care provider visits in the past six months (11.7 vs. 8.9) compared with 
matched controls (n= 286) (all p< .05). ConClusions: DME was more commonly 
reported by patients with diabetes and its presence was associated with a significant 
humanistic and economic burden in the 5EU.
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objeCtives: Hyponatraemia (HN) is estimated to occur in 15% of all hospitalised 
patients with syndrome of inappropriate antidiuretic hormone secretion (SIADH) 
being one of the most common aetiologies. Patients treated with tolvaptan have 
demonstrated improvements in health related quality of life (HRQL) in the SALT I 
& II randomised controlled trials. The objective of this study was to map the SF-12 
responses from SALT I & II to EQ-5D using a publically available algorithm and 
predict the change in EQ-5D associated with tolvaptan. Methods: SF-12 scores 
from the pooled SALT I & II studies were converted to EQ-5D scores using a map-
ping algorithm developed by Gray, et. al 2006. Simulated EQ-5D scores were then 
used to estimate changes in EQ-5D from baseline at day 30 using ordinary least 
squares regression (OLS) as a function of baseline characteristics, treatment arm and 
achievement of sodium correction (NA+) at day 4 (> 135 mmol/l). A preferred model 
was selected based on the highest adjusted R-squared. Secondary analyses looked 
at change from baseline in EQ-5D at day 7, day 14 and at 7 day follow-up following 
treatment discontinuation. Results: The preferred model included baseline age, 
gender, sodium level, EQ-5D and a tolvaptan indicator variable. Based on this model, 
tolvaptan was associated with a positive increase in simulated EQ-5D of 0.10 (n= 164, 
p= 0.03) at day 30 vs. placebo. After 7 days follow-up, tolvaptan was associated with a 
positive, but non- statistically significant effect of 0.04 (n= 74, p= 0.54). No effect was 
observed at day 7 (n= 76, p= 0.90) or at day 14 (n= 85, p= 0.84). Sodium correction did 
not appear to be a statistically significant predictor of HRQL. ConClusions: The 
preferred model indicated a statistically significant improvement in HRQL associ-
ated with tolvaptan use at day 30. Further research is required to establish whether 
sodium correction has an effect of HRQL.
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objeCtives: This 4-wk, Phase 3b, multicentre, open-label, single-arm, outpatient 
study evaluated the safe and effective use of the Single-Use Pen (SUP) in patients 
with type 2 diabetes (T2D) who were naïve to self-injection or injecting others. The 
SUP contains a pre-filled syringe and automates needle insertion, retraction, and 
drug delivery; specifically designed for once-weekly glucagon-like peptide-1 recep-
tor agonist, dulaglutide. Patient-reported outcomes (PROs) related to self-injection 
and to the SUP were important secondary outcomes. Methods: Patients (N= 211) 
were trained on correct injection technique with the SUP containing 0.5 mL placebo 
prior to initial self-injection. PRO measures were completed by patients after final 
injection or at early termination to evaluate device ease of use, experience (including 
satisfaction/confidence), and key device features. Site trainers rated how easy/dif-
ficult it was to train the patient to use the SUP. Results: 99.0% of patients found the 
device easy to use. Patients found it easy to hold the SUP when injecting and to push 
the button to inject (97.6% and 98.1%, respectively). 97.1% of patients were satisfied 
with the overall injection experience, 96.7% of patients were confident they could 
identify when the full dose was delivered, and 99.0% were confident in their overall 
ability to use the SUP. Patients liked not having to attach (99.0%), touch (98.6%), or see 
(95.7%) the needle. 95.7% of patients also liked hearing the click indicating the dose 
was complete and 94.8% liked the automatic needle insertion. Finally, 92.4% of site 
trainers found it easy to train patients on how to use the SUP. ConClusions: This 
study demonstrated the SUP could be used safely and effectively by injection-naïve 
patients with T2D; PRO results indicated patient satisfaction with the SUP injection 
experience. A positive injection experience may be an important factor for some 
patients and providers when initiating injectable therapy.
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objeCtives: Monitoring glycaemic control is important in diabetes clinical trials 
and is also relevant for some oncology trials. It is possible to seamlessly integrate 
blood glucose measurements with clinical trial data via Bluetooth. This integration 
reduces transcription errors and improves accuracy and completeness of data, while 
reducing burden on patients. Our aim was to explore best practices in integrating 
measurements with ePRO. Methods: A review of best practice and experience in 
blood glucose measurement data integration was undertaken and the findings were 
incorporated into a solution for use in clinical trials. A systematic literature review 
was also undertaken to assess the contamination risk to individuals handling and 
re-using electronic diaries (eDiary) previously used by patients doing fingerstick 
tests for blood glucose measurement. We defined search terms and undertook a 
PubMed and internet search. All documents that were identified as possibly relevant 
were reviewed and summarised. Results: The review revealed key features and 
activities related to planning, design, testing and delivery that are important for 
successful integration of blood glucose measurements with ePRO data. The litera-
ture review confirmed that the risk in handling and re-using eDiaries previously 
used by patients doing fingerstick tests was very low. ConClusions: Handling and 
